Autolus Therapeutics Ltd (AUTL) - Total Assets
Based on the latest financial reports, Autolus Therapeutics Ltd (AUTL) holds total assets worth $661.95 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Autolus Therapeutics Ltd (AUTL) shareholders funds for net asset value and shareholders' equity analysis.
Autolus Therapeutics Ltd - Total Assets Trend (2015–2024)
This chart illustrates how Autolus Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data.
Autolus Therapeutics Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Autolus Therapeutics Ltd's total assets of $661.95 Million consist of 84.4% current assets and 15.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 29.1% |
| Accounts Receivable | $48.24 Million | 6.2% |
| Inventory | $4.14 Million | 0.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $12.37 Million | 1.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Autolus Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Autolus Therapeutics Ltd (AUTL) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Autolus Therapeutics Ltd's current assets represent 84.4% of total assets in 2024, an increase from 50.7% in 2015.
- Cash Position: Cash and equivalents constituted 29.1% of total assets in 2024, down from 45.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 45.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 6.2% of total assets.
Autolus Therapeutics Ltd Competitors by Total Assets
Key competitors of Autolus Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Autolus Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.19 | 13.69 | 5.77 |
| Quick Ratio | 5.86 | 13.69 | 5.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $431.51 Million | $665.64 Million | $160.34 Million |
Autolus Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Autolus Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.56 |
| Latest Market Cap to Assets Ratio | 0.50 |
| Asset Growth Rate (YoY) | 108.5% |
| Total Assets | $782.73 Million |
| Market Capitalization | $388.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values Autolus Therapeutics Ltd's assets below their book value (0.50x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Autolus Therapeutics Ltd's assets grew by 108.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Autolus Therapeutics Ltd (2015–2024)
The table below shows the annual total assets of Autolus Therapeutics Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $782.73 Million | +108.51% |
| 2023-12-31 | $375.38 Million | -23.43% |
| 2022-12-31 | $490.27 Million | +20.89% |
| 2021-12-31 | $405.56 Million | +37.83% |
| 2020-12-31 | $294.24 Million | -3.06% |
| 2019-12-31 | $303.53 Million | +39.45% |
| 2018-12-31 | $217.66 Million | 0.00% |
| 2018-09-30 | $217.66 Million | +46.41% |
| 2017-12-31 | $148.66 Million | +334.94% |
| 2016-12-31 | $34.18 Million | +50.87% |
| 2015-12-31 | $22.66 Million | -- |
About Autolus Therapeutics Ltd
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; A… Read more